MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment, given the dependence of prostate cells on androgen and the androgen receptor (AR). However, tumors become ADT-resistant, and there is a need to understand the mechanism. One possible mechanism is the upregulation of AR co...
Saved in:
| Main Authors: | Hannah Weber, Rachel Ruoff, Michael J Garabedian |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS Genetics |
| Online Access: | https://journals.plos.org/plosgenetics/article/file?id=10.1371/journal.pgen.1008540&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
by: Ramesh Narayanan
Published: (2020-07-01) -
Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
by: Trivunić-Dajko Sandra, et al.
Published: (2020-01-01) -
ZFHX3 is integral to androgen/AR signaling involving protein association with AR in prostate cancer cells
by: Xing Fu, et al.
Published: (2025-07-01) -
Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
by: Qiang Dang, et al.
Published: (2015-08-01) -
Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications
by: Pei Zhao, et al.
Published: (2019-01-01)